Images: Related links to external sites (from Bing)
Ontology:
rituximab
(C0393022)
|
Definition (NCI_NCI-GLOSS)
|
A drug used to treat certain types of B-cell non-Hodgkin lymphoma. It is also used with other drugs to treat chronic lymphocytic leukemia and rheumatoid arthritis. It is being studied in the treatment of other types of cancer and other conditions. Rituximab binds to a protein called CD20, which is found on B-cells, and may kill cancer cells. It is a type of monoclonal antibody.
|
|
Definition (NCI)
|
A recombinant chimeric murine/human antibody directed against the CD20 antigen, a hydrophobic transmembrane protein located on normal pre-B and mature B lymphocytes. Following binding, rituximab triggers a host cytotoxic immune response against CD20-positive cells. (NCI04)
|
|
Definition (PDQ)
|
A recombinant chimeric murine/human antibody directed against the CD20 antigen, a hydrophobic transmembrane protein located on normal pre-B and mature B lymphocytes. Following binding, rituximab triggers a host cytotoxic immune response against CD20-positive cells. Check for "http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=42613&idtype=1" active clinical trials or "http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=42613&idtype=1&closed=1" closed clinical trials using this agent. ("http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C1702" NCI Thesaurus)
|
| Concepts |
Pharmacologic Substance
(T121)
, Amino Acid, Peptide, or Protein
(T116)
, Immunologic Factor
(T129)
|
| MSH |
C092560
|
| SnomedCT |
108809004, 386919002 |
| English |
Chimeric Anti-CD20 Antibody, C2B8 Monoclonal Antibody, monoclonal antibody anti-CD20, CD20 antibody, rituximab, rituximab, rituximab (medication), rituximab [Chemical/Ingredient], riTUXimab, Rituximab Biosimilar BI 695500, BI 695500, Rituximab, Rituximab (product), Rituximab (substance), anti-CD20 monoclonal antibody, RITUXIMAB |
| Spanish |
rituximab (producto), rituximab (sustancia), rituximab |
